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ABSTRACT We	  have	  begun	  work	  on	  two	  separate	  but	  related	  ontologies	  for	  the	  study	   of	   neurological	   diseases.	   	   The	   first,	   the	   Neurological	   Disease	  Ontology	  (ND),	  is	  intended	  to	  provide	  a	  set	  of	  controlled,	  logically	  con-­‐nected	  classes	  to	  describe	  the	  range	  of	  neurological	  diseases	  and	  their	  associated	  signs	  and	  symptoms,	  assessments,	  diagnoses,	  and	  interven-­‐tions	  that	  are	  encountered	  in	  the	  course	  of	  clinical	  practice.	  	  ND	  is	  built	  as	  an	  extension	  of	  the	  Ontology	  for	  General	  Medical	  Sciences	  —	  a	  high-­‐level	   candidate	  OBO	   Foundry	   ontology	   that	   provides	   a	   set	   of	   general	  classes	  that	  can	  be	  used	  to	  describe	  general	  aspects	  of	  medical	  science.	  ND	   is	   being	   built	   with	   classes	   utilizing	   both	   textual	   and	   axiomatized	  definitions	  that	  describe	  and	  formalize	  the	  relations	  between	  instances	  of	  other	  classes	  within	  the	  ontology	  itself	  as	  well	  as	  to	  external	  ontolo-­‐gies	   such	   as	   the	   Gene	  Ontology,	   Cell	   Ontology,	   Protein	  Ontology,	   and	  Chemical	  Entities	  of	  Biological	  Interest.	  In	  addition,	  references	  to	  simi-­‐lar	  or	  associated	  terms	  in	  external	  ontologies,	  vocabularies	  and	  termi-­‐nologies	  are	  included	  when	  possible.	  Initial	  work	  on	  ND	  is	  focused	  on	  the	  areas	  of	  Alzheimer’s	  and	  other	  diseases	  associated	  with	  dementia,	  multiple	  sclerosis,	  and	  stroke	  and	  cerebrovascular	  disease.	  Extensions	  to	  additional	  groups	  of	  neurological	  diseases	  are	  planned.	  The	   second	   ontology,	   the	   NeuroPsychological	   Testing	   Ontology	  (NPT),	  is	  intended	  to	  provide	  a	  set	  of	  classes	  for	  the	  annotation	  of	  neu-­‐ropsychological	  testing	  data.	  	  The	  intention	  of	  this	  ontology	  is	  to	  allow	  for	  the	  integration	  of	  results	  from	  a	  variety	  of	  neuropsychological	  tests	  that	   assay	   similar	   measures	   of	   cognitive	   functioning.	   Neuro-­‐psychological	   testing	   is	   an	   important	   component	   in	   developing	   the	  clinical	  picture	  used	  in	  the	  diagnosis	  of	  patients	  with	  a	  range	  of	  neuro-­‐logical	  diseases,	  such	  as	  Alzheimer’s	  disease	  and	  multiple	  sclerosis,	  and	  following	  stroke	  or	  traumatic	  brain	  injury.	  	  NPT	  is	  being	  developed	  as	  an	  extension	  to	  the	  Ontology	  for	  Biomedical	  Investigations.	  
1 INTRODUCTION  
The field of neurology deals with a diverse domain of dis-
eases related to the functioning of the nervous system in all 
its aspects, including diseases resulting from disorders of 
the central, peripheral, and autonomic nervous systems.  
Neurological diseases may exhibit both acute and chronic 
courses, affect a variety of cell types and anatomical regions 
of the body. They are manifested via a variety of mecha-
nisms, including cell-autonomous disorders, unregulated 
protein aggregation, autoimmune conditions, and vascular 
pathology, which, depending on the disease, may occur 
alone or together in various combinations (Ropper et al., 
2005; Merritt and Rowland, 2000). At a different level of 
granularity we see neurological diseases that affect cogni-
tive as well as mental functioning. Following Ceusters and 
Smith (2010), we maintain that mental diseases are (at least 
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primarily) special kinds of neurological diseases in the sense 
that the disorder, which serves as the material basis for the 
disease, is a part of an anatomical structure in the organism 
responsible for producing and maintaining cognitive repre-
sentations and behavior. For example, a variety of neuro-
logical conditions result in dementia, such as Alzheimer’s 
and Parkinson's disease, and many of the late-onset leu-
kodystrophies.  
We have recently begun building a new ontology for the 
domain of neurological diseases – the Neurological Disease 
Ontology (ND).  ND is an ongoing project that aims to ac-
curately represent every facet of neurological diseases in as 
much detail as possible.  This includes their clinical presen-
tation, diagnosis, treatment, physical manifestation, course 
of development, genetic and physical bases, and more.  ND 
is still in the early stages of development, but is rapidly 
growing to include more of these facets.  While our ultimate 
goal in developing ND is to provide a comprehensive ac-
count of all neurological diseases, it has three initial areas of 
focus: Alzheimer’s disease (AD), multiple sclerosis (MS), 
and stroke and cerebrovascular events.  At this time, the 
most progress has been made on AD and other diseases that 
result in dementia, but work is currently under way on rep-
resenting MS and associated demyelinating diseases as well 
as on representing stroke and cerebrovascular disease. 
As a corollary to ND, we have begun development of the 
NeuroPsychological Testing Ontology (NPT) to represent 
neuropsychological assessments such as the Folstein Mini-
Mental State Examination (MMSE), the Trail- Making Test, 
the Hopkins Verbal Learning Test, and the Wechsler Mem-
ory Scale. These standardized assessments are useful for 
identifying the presence and degree of cognitive impairment 
in patients (Lezak et al., 2004). An initial goal of the NPT 
project is to test hypotheses about the diagnosis of AD 
based on the results of neuropsychological assessments. Part 
of the development of NPT necessitates reference to aspects 
of cognitive functioning. For example, MMSE produces 
scores that are indicative of impairment in certain functional 
cognitive domains such as language, executive function, or 
memory. A challenge we have encountered is how to con-
nect these commonly described cognitive domains to func-
tioning on the side of the organism. We see this as an ex-
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cellent opportunity to connect ND and NPT with work in 
the Mental Functioning Ontology (MF) as well as with the 
Mental Disease Ontology (MD). Ideally we hope to drive 
development in both. For example, an extension of MD that 
represents dementia from the perspective of it being a men-
tal disease or syndrome could then be linked via logically 
defined relations to classes in ND. 
We plan to build ND over the long-term in a collabora-
tive manner with other groups focused on representing par-
ticular neurological diseases as modules within ND.  Our 
work is intended to be OBO-Foundry compliant and builds 
upon the paradigm established by Ontology for General 
Medical Sciences (OGMS) for the representation of entities 
in the domain of medicine and disease (Scheuermann et al. 
2009). 
 
2 METHODS 
ND and NPT are being curated using both top-down and 
bottom-up approaches to the creation of classes within the 
ontology.  A major aspect of the top-down approach for ND 
has involved analyzing what types of neurological diseases 
exist and how they ought to be represented within the ontol-
ogy according to their relevant characteristics.  Of some 
concern is how our strategy will fit with other disease on-
tologies.  A key element includes deciding what other types 
of entities should be represented in ND in order to accu-
rately represent the neurological diseases as well as how the 
relationships between these classes should be represented.  
For instance, the class ‘neurological disease’ currently in-
cludes ‘neurodegenerative disease’, ‘infectious neurological 
disease’, ‘demyelinating disease’, and ‘vascular neurologi-
cal disease’ as four of its subclasses.  The inclusion of these 
subclasses was driven by our decision to focus, as much as 
possible, on representing neurological diseases from the 
perspective of their etiology.  For example, it is part of the 
logical definition for ‘neurodegenerative disease’ that all 
realizations of these diseases involve some process of neu-
rodegeneration. This top-down approach provides ND with 
its primary structure. 
Due to the complex nature of neurological diseases, as 
well as the diversity of perspectives from which they are 
studied and classified, we have also included additional im-
mediate subclasses of ‘neurological disease’.  For example, 
‘central nervous system disease’ and ‘peripheral nervous 
system disease’ are included as subclasses of ‘neurological 
disease’.  Currently we do not explicitly assert any disease 
Figure 1: A subset of OGMS and ND and some connections to external ontologies. 
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as a subclasses of these classes, however ND is being built 
using axioms that will allow an ontological reasoner to 
automatically create an inferred hierarchy of neurological 
disease types based on anatomical structure or genetic basis. 
This approach allows ND more versatility without commit-
ting it to a single perspective or creating confusion by 
switching between perspectives within the asserted hierar-
chy.  Another example of this approach is creation of the 
defined class ‘disease resulting in dementia’, which has a 
limited number of asserted subclasses, and was created to 
provide a reference class from which to allow a reasoner to 
infer a hierarchy of all diseases that result in dementia. 
While the top-down aspect of the project is essential to 
shaping the development of ND, it is the bottom-up aspect 
of the project that provides the bulk of the information.  In 
particular, it is this approach that results in the creation and 
refinement of the definitions for terms in ND.  We have 
consulted primary research articles, review articles, medical 
professionals, and other sources to inform the development 
of ND.  This process has led to the inclusion of new terms in 
ND as well as more detailed classifications of particular 
neurological diseases. Both approaches are necessary for the 
completion of the project. 
Development of NPT is based upon analyses of neuro-
psychological tests to drive the development of classes for 
the representation of neurological assays and their results.  
Many neuropsychological tests have multiple subtests, and 
these are being captured within the ontology as well. Neu-
ropsychological tests assay domains such as verbal and vis-
ual-spatial memory, executive function, and linguistic func-
tions.  NPT is being developed to allow the integration of 
scores from different neuropsychological tests and subtests 
so that results for patients who have been tested using dif-
ferent protocols can be queried and grouped appropriately. 
ND and NPT are built using Protégé 4.1 as OWL2 on-
tologies. The importation of classes from other ontologies 
according to the MIREOT standard has been achieved using 
OntoFox (Xiang, 2010). 
Both ND and NPT are being developed according to 
OBO Foundry principles (Smith et al., 2007) and is being 
done in cooperation with the related efforts to develop 
ontologies for representing Mental Disease (MD) and 
Mental Functioning (MF) (Hastings et al. 2012a and 
2012b). 
3 RESULTS 
The Neurological Disease Ontology is being built according 
to OBO Foundry principles as an extension of OGMS, 
which provides a set of general reference classes related to 
diseases, their patients, and diagnoses (Scheuermann et al. 
2009). OGMS follows the paradigm of the Basic Formal 
Ontology (BFO). Figure 1 illustrates the layers of granular-
Ontology Name Use in ND 
Basic Formal Ontology (BFO) Top-level reference ontology 
Ontology for General Medical Sciences (OGMS) Mid-level reference ontology 
NIF-Dysfunction and Disease Ontology (DO) Externally referenced disease classes 
Relation Ontology (RO) Imported relation types 
Protein Ontology (PR) Select classes for proteins imported via MIREOT 
Foundational Model of Anatomy (FMA) Select classes for anatomical structures imported via MIREOT 
IAO, PATO, ChEBI, GO, CL, and OBI Select classes imported via MIREOT 
Table 1. External ontologies used by the Neurological Disease Ontology.  
Figure 2: A	  portion	  of	  the	  ND	  disease	  hierarchy. 
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ity captured by the relations between ND, OGMS, and BFO 
as well as IAO and OBI. Furthermore, we are ensuring that 
ND is compliant with the pre-release revised version of 
BFO – BFO 2.0, and the revised version of OGMS that is 
also compliant with BFO 2.0. 
In building ND, we have relied upon a number of 
sources, including reference works, review articles, and 
other ontologies, such as NIF-Dysfunction and the Disease 
Ontology (DO) (Bug et al., 2008; Larson & Martone, 2009). 
Based on these sources we have curated a high-level disease 
hierarchy that we believe presents a useful initial approach 
to categorizing neurological diseases, a section of which is 
shown in Figure 2. We go beyond earlier efforts at creating 
disease ontologies by providing textual definitions for every 
disease class and by incorporating logical definitions in or-
der to relate classes for diseases and other entities in ND to 
other classes in ND and to separate ontologies (See Table 1 
for a summary). 
These high level disease classes provide a framework for 
the in depth curation of ND ontology modules intended to 
represent neurological diseases in extensive detail. At the 
University at Buffalo, our initial efforts are focused upon 
the areas of Alzheimer’s disease and other diseases resulting 
in dementia, multiple sclerosis, and stroke and cerebrovas-
cular disease. As an early stage ontology development pro-
ject, ND currently contains approximately 400 classes; 
about 250 classes have textual definitions; more than 50 
classes have logical definitions; more than 150 classes have 
external references; and there are nearly 200 children of the 
class ‘disease’.  In addition to disease classes, ND has a 
heavy focus on diagnosis, syndrome, disorder, and protein 
classes among others in order to fully represent all of the 
various aspects of neurological diseases. 
In building NPT we have relied upon source tests, such 
as the Folstein Mini-Mental State Exam, as well as upon 
textbooks and articles about particular neuropsychological 
tests (Lezak et al., 2004; Mitrushina et al., 2005). NPT is 
built using the schema for representing assays that has been 
developed in OBI and consequently currently imports all of 
OBI. At a later point, we will rely upon a slimmed (MIR-
EOTed) version of OBI. At the moment, there are more than 
250 NPT specific classes, but we expect this to grow 
quickly as we add representations of additional neuropsy-
chological tests. Figure 3 shows a portion of NPT for the 
representation of the MMSE. 
4 DISCUSSION 
Our use cases in building these ontologies include annota-
tion of clinical studies in neurology as well as annotation of 
patient records. Particularly for the latter case we expect ND 
and NPT to complement each other, with ND providing 
terms for representing the diagnoses of patients based on 
their signs and symptoms, and associated phenotypes. NPT 
will provide a very detailed set of classes for annotation of 
neuropsychological measures that may be used in the forma-
tion of a patient’s clinical picture, which is used to reach a 
diagnosis.  These diagnostic conclusions are annotated as an 
Figure 3: A portion of the representation of the MMSE assay in NPT. 
Ontologies for the Study of Neurological Disease 
5 
instance of a diagnosis class in ND. The diagnosis classes 
are linked to the disease classes in ND, which themselves 
link via their logical definitions to other classes in ND such 
as the disorder which serves as the material basis of the dis-
ease, and then, in turn, to other ontologies such as PR. 
In developing ND and NPT we recognize the need to co-
ordinate with other ontology development efforts in related 
domains. In Ceusters and Smith (2010), for instance, the 
framework for what are now named the Mental Functioning 
Ontology (MF) and the Mental Disease Ontology (MD) was 
presented. Neurological diseases by their very nature often 
affect cognitive and mental functioning, for instance in any 
disease that results in dementia, such as Alzheimer’s dis-
ease, and often lead to mental diseases, such as depression 
in MS or epilepsy patients. In developing ND we will need 
to ensure representation of conditions such as dementia or 
depression are coordinated with MF and MD, such that a 
class representing a clinical phenotype of “depression in 
conjunction with multiple sclerosis” may have a parent class 
of “depression” in MD. Moreover we feel that our work can 
aid in a bottom-up approach to developing MD and MF. 
Furthermore, we believe our work on NPT will be valu-
able for the annotation of neuropsychological data not just 
for patients with neurological disease, but also for studies of 
general mental functioning and in testing in patients with 
mental diseases.  Thus, our work on NPT will hopefully 
prove of value for a number of related domains in addition 
to that of neurological diseases, and will eventually be com-
plemented by ontologies for other types of assessments of 
nervous system function and anatomy, such as an MRI im-
aging ontology. 
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